VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
-5.2%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$824M
AUM Growth
+$824M
(-11%)
Cap. Flow
+$30.2M
Cap. Flow
% of AUM
3.67%
Top 10 Holdings %
Top 10 Hldgs %
67.68%
Holding
37
New
9
Increased
2
Reduced
6
Closed
8
Top Buys
| 1 |
LENZ
LENZ Therapeutics
LENZ
|
$49.6M |
| 2 |
GH Research
GHRS
|
$27.7M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$25M |
| 4 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
$24.5M |
| 5 |
CVRx
CVRX
|
$17.7M |
Top Sells
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$94M |
| 2 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$19.8M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$13.2M |
| 4 |
APTO
Aptose Biosciences, Inc.
APTO
|
$9.59M |
| 5 |
Adicet Bio
ACET
|
$8.4M |
Sector Composition
| 1 | Healthcare | 91.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HARP
26
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $7.1M | 0.86% |
+512,005
| New | +$7.1M |
|
27
Astria Therapeutics
ATXS
$394M
| $6.82M | 0.83% |
+3,234,000
| New | +$6.82M |
|
|
28
Adicet Bio
ACET
$60.8M
| $1.89M | 0.23% |
183,702
-816,298
| -82% | -$8.4M |
|
29
Viridian Therapeutics
VRDN
$1.59B
| $357K | 0.04% |
19,495
| – | – |
|
|
CNST
30
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| – | – |
-4,016,873
| Closed | -$94M |
|
|
MTCR
31
DELISTED
Metacrine, Inc. Common Stock
MTCR
| – | – |
-680,000
| Closed | -$4.22M |
|
|
APTO
32
DELISTED
Aptose Biosciences, Inc.
APTO
| – | – |
-1,605,400
| Closed | -$9.59M |
|
33
Taysha Gene Therapies
TSHA
$791M
| – | – |
-120,649
| Closed | -$2.45M |
|
34
Tango Therapeutics
TNGX
$745M
| – | – |
-500,000
| Closed | -$5.56M |
|
35
ARS Pharmaceuticals
SPRY
$1.08B
| – | – |
-85,000
| Closed | -$3.71M |
|
|
36
Syndax Pharmaceuticals
SNDX
$1.39B
| – | – |
-591,782
| Closed | -$13.2M |
|
37
EyePoint Pharmaceuticals
EYPT
$827M
| – | – |
-700,000
| Closed | -$7.11M |
|